- Home
- CAPR vs CLW Comparison
CAPR vs CLW Comparison
Compare CAPR & CLW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- CLW
- Stock Information
- Founded
- CAPR 2005
- CLW 2005
- Country
- CAPR United States
- CLW United States
- Employees
- CAPR N/A
- CLW N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- CLW Paper
- Sector
- CAPR Health Care
- CLW Basic Materials
- Exchange
- CAPR Nasdaq
- CLW Nasdaq
- Market Cap
- CAPR 324.6M
- CLW 348.3M
- IPO Year
- CAPR N/A
- CLW N/A
- Fundamental
- Price
- CAPR $6.36
- CLW $21.38
- Analyst Decision
- CAPR Strong Buy
- CLW Buy
- Analyst Count
- CAPR 8
- CLW 1
- Target Price
- CAPR $24.75
- CLW $36.00
- AVG Volume (30 Days)
- CAPR 1.2M
- CLW 172.4K
- Earning Date
- CAPR 11-12-2025
- CLW 11-03-2025
- Dividend Yield
- CAPR N/A
- CLW N/A
- EPS Growth
- CAPR N/A
- CLW 345.10
- EPS
- CAPR N/A
- CLW 12.12
- Revenue
- CAPR $13,392,150.00
- CLW $1,550,400,000.00
- Revenue This Year
- CAPR N/A
- CLW $12.75
- Revenue Next Year
- CAPR $6,061.53
- CLW $1.60
- P/E Ratio
- CAPR N/A
- CLW $1.77
- Revenue Growth
- CAPR N/A
- CLW 34.73
- 52 Week Low
- CAPR $4.05
- CLW $20.84
- 52 Week High
- CAPR $23.40
- CLW $33.57
- Technical
- Relative Strength Index (RSI)
- CAPR 42.32
- CLW 40.09
- Support Level
- CAPR $6.05
- CLW $21.08
- Resistance Level
- CAPR $6.62
- CLW $22.46
- Average True Range (ATR)
- CAPR 0.39
- CLW 0.57
- MACD
- CAPR 0.05
- CLW 0.20
- Stochastic Oscillator
- CAPR 47.89
- CLW 21.74
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About CLW Clearwater Paper Corporation
Clearwater Paper Corp is engaged in the manufacturing and supplier of Solid Bleached Sulfate (SBS) paperboard packaging products. The company products includes: SBS paperboard which is a premium paperboard grade that is frequently used to produce folding cartons, food service, commercial printing items. It generates maximum revenue from Pulp and Paperboard segment. Company operate in United States and have globalized access too. Geographically, it derives maximum revenue from the United States.